SHS Capital acquires Curatec Services with subsidiary MTR

Tübin­gen — Health­care specia­list SHS Capi­tal, toge­ther with its port­fo­lio company Medi­zin­tech­nik Rostock GmbH (MTR), is acqui­ring Cura­tec Services GmbH, a specia­li­zed provi­der of medi­cal elec­tro­sti­mu­la­tion and reha­bi­li­ta­tion devices.

The aim of the tran­sac­tion is to ensure the successful succes­sion of Cura­tec, to expand MTR’s product port­fo­lio in the field of neuro­lo­gi­cal appli­ca­ti­ons, func­tional elec­tri­cal stimu­la­tion (FES) and incon­ti­nence therapy and to further expand the joint market posi­tion in the field of elec­tri­cal stimulation.

Cura­tec, based in North Rhine-West­­pha­­lia, has more than 25 years of expe­ri­ence in home elec­tro­sti­mu­la­tion therapy and has earned an excel­lent repu­ta­tion with high-quality medi­cal products, a strong pati­ent-orien­­ted service and estab­lished rela­ti­onships with clinics, specia­list prac­ti­ces, home­care provi­ders and statu­tory health insu­rance companies.

“We are deligh­ted that SHS will conti­nue and further expand our busi­ness toge­ther with MTR. Our grea­test concern was to ensure that the trust in the quality of our work that has been built up over many years remains intact and conti­nues to bene­fit the pati­ents who so urgen­tly need our products,” says Cura­tec Mana­ging Direc­tor Rainer Eckert.

“By acqui­ring Cura­tec, we are streng­thening our joint market presence and will have an even more compre­hen­sive product port­fo­lio in the field of elec­tro­sti­mu­la­tion therapy in future. This part­ner­ship crea­tes an excel­lent basis for further growth and the highest quality in pati­ent care,” comm­ents MTR Mana­ging Direc­tor Andreas Mark­schies.

“This acqui­si­tion exem­pli­fies SHS’s approach of successfully leading inno­va­tive medi­cal tech­no­logy compa­nies into the next gene­ra­tion, crea­ting sustainable succes­sion solu­ti­ons and thus secu­ring pati­ent care in the long term. We are deligh­ted to have found a company in Cura­tec that ideally comple­ments MTR both in terms of its product port­fo­lio and its regio­nal presence,” explains SHS Senior Invest­ment Mana­ger Tobias Fuchs (photo: SHS).

About SHS Capital

The sector inves­tor SHS is a private equity provi­der foun­ded in 1993 that makes invest­ments in health­care compa­nies in Europe. The focus of invest­ments is on expan­sion finan­cing, share­hol­der chan­ges and succes­sion situa­tions. “Buil­ding Euro­pean Health­care Cham­pi­ons” is the invest­ment philo­so­phy accor­ding to which SHS finan­ces and deve­lops its port­fo­lio compa­nies. The Tübin­­gen-based inves­tor is taking both mino­rity and majo­rity stakes. SHS funds’ natio­nal and inter­na­tio­nal inves­tors include pension funds, funds of funds, foun­da­ti­ons, family offices, stra­te­gic inves­tors, entre­pre­neurs and the SHS manage­ment team. The equity or equity-like invest­ment of the AIF amounts to up to € 50 million. Volu­mes in excess of this can be reali­zed with a network of co-inves­­tors. In its invest­ment decis­i­ons, SHS places strong empha­sis on the conside­ra­tion of ESG aspects and has ther­e­fore commit­ted itself to the guide­lines of the UN PRI. SHS is curr­ently inves­t­ing from its sixth fund, which was laun­ched in 2022 and has a volume of around € 270m. — www.shs-capital.eu